Efficacy Study of Paclitaxel Versus Irinotecan in Patients With Recurrent or Metastatic Gastric Cancer Who Progress Following First-line Therapy

NCT01224652 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

518

Enrollment

OTHER

Sponsor class

Conditions

Gastric Cancer

Interventions

DRUG: Paclitaxel
DRUG: Irinotecan

Sponsor

Korean Cancer Study Group

Collaborators

[object Object]